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Conventional cytology such as sputum, bronchial brushes, washes 
and lavages and ﬁne needle aspiration biospy (FNA) have long played 
a role in the diagnosis of primary and metastatic lung cancers. The 
separation of small cell lung cancer from non small cell lung can-
cer (NSCLC), especially in cytologic material, has historically been 
deemed sufﬁcient for purposes of patient treatment. Small cell carcino-
ma was treated by chemotherapy and NSCLC underwent surgery ﬁrst 
and then chemotherapy where appropriate. The separation of NSCLC 
into adenocarcinoma and its subtypes and squamous cell carcinomas 
was not necessary. In the era of targeted therapy this approach is no 
longer adequate.
Cytologic preparations can allow the distinction of adenocarcinoma 
subtypes, particularly bronchioloalveolar, and the recognition of squa-
mous cell carcinoma.
The use of immunohistochemical stains such as TTF-1, CK7, CK20, 
4A4, 34βE12 and p63 can be applied to cytologic material to help 
make these distinctions. In additon, cytology material such as cells 
blocks can be utilzed for EGFR gene mutation studies.
Speciﬁc cytologic ﬁndings associated with the presence of BAC or 
adenocarcinoma with a BAC component can be identiﬁed in cytologic 
preparatins. These ﬁndings include ﬂat sheets of epithelial cells, nuclear 
inclusions and grooves and lack of prominent nucleoli.
The role of cytology in the diagnosis and management of lung cancer is 
of increasing importance and cytology can be used to provide excellent 
and accurate classiﬁcations of lung tumors. 
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Undertaking frozen sections (FSs) is a well-established and diagnosti-
cally accurate procedure that aids in the intra-operative staging of 
many cancers (1). The European Society of Thoracic Surgeons (ESTS) 
have recently published guidelines relating to intraoperative lymph 
node staging, and the pathologic evaluation of resected lymph nodes 
in patients with non-small cell lung cancer (NSCLC) with the aim of 
standardising management (2). A standardised approach to FS analysis 
of bronchial resection margins has also been recently proposed that 
highlights the difference between direct growth of invasive non-small 
cell carcinoma, lymphangitic spread and carcinoma-in situ (3)
In an effort to reﬁne the above, there have also been recent studies 
assessing whether identiﬁcation of sentinel nodes for frozen section 
may inﬂuence extent of resection and number of nodes required to be 
assessed during operation, with varying degrees of success (4,5).
The increased reﬁnement of adenocarcinoma diagnosis in relation to 
the patterns identiﬁed in the WHO classiﬁcation (6) and the Noguchi 
classiﬁcation (7) has also led to groups assessing how far this can be 
taken at FS, as limited resection could be an acceptable alternative for 
some patients with ÎearlyÌ disease. One study has shown that, in small 
(< or = 10 mm) peripheral adenocarcinomas, FS may be used to apply 
Noguchi’s classiﬁcation, particularly types A and B, in which there may 
be intent to limited surgery (8). Using imprint cytology, there are also 
cytological factors that can predict invasion in small-sized peripheral 
lung adenocarcinoma with a bronchioloalveolar carcinoma component. 
In one study, univariate analysis identiﬁed ﬁve cytologic factors that 
were associated signiﬁcantly with invasion (presence of tumour clusters 
comprising more than 50 tumour cells, nuclear overlap in more than 
three layers, presence of nuclear grooves, more than 3-fold variation 
in nuclear size, and 1 mitosis per 1000 tumour cells). Among these, 
nuclear overlapping in more than three layers and more than 3-fold 
variation in nuclear size were found to be independent predictive fac-
tors for invasion by multivariate analysis (9).
Another problem area, particularly in the lung, is when there is a his-
tory of previous malignancy. Differentiating primary from metastatic 
carcinomas can be difﬁcult, especially with poorer morphology on FS 
and no histological feature is 100% speciﬁc (10). In parafﬁn-embedded 
tissue, an immunohistochemical panel is typically used to in addition 
to morphology to assess cytokeratin proﬁles (e.g. 7 and 20) and the 
presence/absence of more organ-speciﬁcÌ epitopes such as thyroid tran-
scription factor-1 (TTF-1) and hormone receptors. Of these TTF-1 is 
the most valuable as it is highly speciﬁc and sensitive for primary lung 
tumours, excluding thyroid neoplasms (11,12). The ability to undertake 
intra-operative immunohistochemstry would therefore be of potential 
value as distinction of the type of tumour at this timepoint could inﬂu-
ence surgery (anatomic resection for primary lung cancer and more 
localised resection for metastatic disease) (13,14) and methodology that 
permits this within the timeframe of a thoracotomy and with similar 
speciﬁcity and sensitivity to that seen for formalin-ﬁxed tissues has 
recently become available (FSIHC) (15).
In a prospective study over two years, this additional immunohisto-
chemical data at the time of operation increased diagnostic conﬁdence 
in all cases, particularly in cases that were positive for TTF-1 (16). 
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Overall, whether positive or negative, FSIHC increased conﬁdence 
82% (ranging from 50% to 99%) to 96% (60% to 100%). In those 
with metastatic colonic adenocarcinoma, changes in the conﬁdence of 
diagnosis for went from 88% (ranging from 65% to 99%) to 95% (60% 
to 100%) after FS-IHC. FS-IHC was particularly useful when samples 
were of small size and architectural features that often help distinguish 
primary from metastatic disease were lacking. The average time taken 
per test was 24 minutes at an estimated additional cost of £32 ($57). 
This technique is now part of our routine diagnostic practice, although 
is not used on every occasion as histological features alone often allow 
sufﬁcient diagnostic conﬁdence, especially in relation to metastases 
from the large bowel. However, this will be counterbalanced by the 
experience of the reporting pathologist and the case mix, so that usage 
rates in other institutions may prove higher. 
Although undoubtedly useful, FSIHC must be interpreted in the context 
of clinical and imaging presentation as well as routine histological 
features, as rare false positives can occur with TTF-1 and we have 
had one such case with an FSIHC. The time limit of 24 minutes and 
manpower issues also mean that all lesions (when multiple) cannot be 
assessed and since we started using this technique, one or more of the 
pulmonary masses have proven to be primary tumours arising synchro-
nously with metastatic disease in four cases. Even with close pre-op-
erative review, it is unlikely that such cases could be identiﬁed. Other 
groups have also shown that FSIHC for TTF-1 can be of diagnostic 
value (17) and similar techniques have been used for other antibodies 
(e.g. cytokeratins) in relation to carcinomas at other sites (18,19), but 
future usage must be weighed up against the value of the information 
that the technique provides so as not to place unnecessary workloads on 
pathology laboratories.
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Recent progress in radiologic imaging methods such as thin-section CT 
and/or high-resolution CT has improved the ability to diagnose small 
adenocarcinomas less than 2 cm in diameter. Such small-sized adeno-
carcinomas comprise two groups: replacement-type, and non-replace-
ment-type adenocarcinoma. Replacement-type adenocarcinoma, show-
ing a bronchioloalveolar carcinoma (BAC) component, is subdivided 
into three subtypes: localized BAC (LBAC) (type A), LBAC with alve-
olar collapse (type B), and LBAC with foci of ﬁbroblastic proliferation 
(type C). Non-replacement-type adenocarcinoma is also subdivided 
into three subtypes: solid adenocarcinoma with mucin formation (type 
D), tubular adenocarcinoma (type E), and papillary adenocarcinoma 
(type F). The non-replacement-type adenocarcinomas are invasive and 
have an unfavorable prognosis, whereas the replacement-type adeno-
carcinomas are a mixed group that include non-invasive carcinomas 
with an extremely favorable prognosis (types A and B, 5-year survival 
rate 100%) and early invasive or microinvasive adenocarcinoma (type 
C, 5-year survival rate 75%) (1). Most of the cases detected by CT 
screening are replacement-type adenocarcinomas, which are targets 
for reduction or limited surgery such as wedge resection or segmen-
tectomy, since they comprise a mixed population that includes tumors 
with an extremely favorable prognosis or a poor prognosis. Therefore, 
there is a need for reliable morphologic and/or immunohistochemical 
markers to discriminate less-aggressive tumors.
A number of factors are reportedly useful for prognostication of non-
small cell carcinoma and/or adenocarcinoma. However, these factors 
have not been compared sufﬁciently, especially in relation to small-
sized early adenocarcinoma. In the present study, ten immunohisto-
chemical prognostic factors reported previously ? CEA, p53, MIB1, 
p27, EGFR, pEGFR, Cox2, Neurnatin, γH2AX, and TTF-1 ? were 
selected, and their usefulness was compared using the same series of 
small-sized adenocarcinomas. Furthermore, the ratios of the BAC com-
ponent and micropapillary component in the largest cut surface of the 
tumor were examined as histologic factors. Abnormalities of the p53, 
K-ras, and EGFR genes were also examined. One hundred and thirty-
eight consecutive patients were selected. All underwent complete resec-
tion of small-sized adenocarcinomas at the National Cancer Center 
Hospital (Tokyo, Japan), and did not receive any chemotherapy and/or 
radiotherapy prior to surgery. Among the prognostic factors examined, 
